fb-pixel tracker

Profile Menu

MI Profile for U.S. (excluding New York)

MI Profile is a multi-platform, solid tumor biomarker analysis for therapeutic decision support and clinical trials matching. Technologies used to assess DNA, RNA and Proteins include, Next-Generation Sequencing DNA/RNA (also called MI Tumor Seek), Pyro Sequencing, Fragment Analysis, Immunohistochemistry and Chromogenic in situ Hybridization.

The information below details the biomarkers tested and technology platforms utilized by tumor type.

View the full MI Profile Menu for U.S. here:  Profile Menu Brochure

  • Whole Exome Sequencing (WES) analysis of DNA for mutations, copy number alterations*, insertions/deletions, genomic signatures (LOH, MSI, TMB*) is currently performed for all tumor types. Colorectal cancer receives 592-gene Next-Generation (DNA) Sequencing.
    * Not Available in New York State.
  • In certain instances, some biomarkers included in MI Profile or genes ordered individually will not associate with commercially available cancer therapies or clinical trials.
  • For PD-L1 IHC testing, Dako antibodies 22c3, 28-8 and antibody SP-142 are used as appropriate.
  • For certain patients, HER2 testing is performed by Chromogenic in situ Hybridization, in addition to Next-Generation Sequencing.
  • For certain patients, MSI testing is performed by Fragment Analysis.
  • View the full Reflex Testing Menu here: Reflex Testing Menu
Share This Page

Precision Oncology Starts Here

Uncover molecular insights through comprehensive interrogation of DNA, RNA and Proteins to personalize treatment options.